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Myelodysplastic syndrome (MDS) has long been presumed to be a stem cell disorder, but rigorous formal
proof has been lacking. In this issue of Cancer Cell, Woll and colleagues demonstrate that driver mutations
occurring in MDS definitively occur in cells with a stem cell phenotype.Figure 1. Driver Mutations Found in Bulk MDS Cells Are also Seen in MDS Stem Cells
Cells fromMDS bone marrow were sorted by stem cell markers, and sequencing for driver mutations was
performed on both unsorted and sorted populations. All of the mutations seen in sorted stem cells were
identical to mutations in the bulk population.Myelodysplastic syndrome (MDS) is
comprised of a heterogeneous set of
disorders characterized by ineffective
hematopoiesis, morphologic dysplasia of
one or more hematopoietic lineages in
the marrow, and progression to acute
myeloid leukemia (AML) in some cases.
Early evidence for a stem cell origin for
these disorders was provided by clonal
detection of skewed X chromosome inac-
tivation patterns and the identification of
characteristic chromosomal abnormal-
ities in cells of multiple lineages from
MDS patients (Gerritsen et al., 1992;
Janssen et al., 1989); however, formal
demonstration that MDS is a stem cell
disorder at the genetic level has been
limited (Nilsson et al., 2000).
Aparadigm that has taken root in cancer
biology over the last several years is the
cancer stem cell hypothesis (Reya et al.,
2001). This hypothesis states that cancer
occurs by acquisition of genetic or epige-
netic changes until the normal cell of origin
has been phenotypically altered such that
it is capable of fully propagating the tumor.
In normal ontogeny, only true tissue stem
cells possess life-long self-renewal poten-
tial; thus, driver mutations must occur in
bona fide stem cells unless the mutations
are able to directly confer this potential
on committed progenitors. Evidence for
the cancer stem cell hypothesis has
largely been limited to tumor xenograft
models, and direct demonstration of their
existence in humans cancers has only
come through recent studies that have at-
tempted to identify genetic lesions in ‘‘pre-
leukemic’’ stem cells from AML patients
(Jan et al., 2012; Shlush et al., 2014).
The spectrum of driver mutations in
MDS and the clinical impact has been re-
vealed by high-throughput sequencing
studies on large numbers of MDS sam-ples (Bejar et al., 2011; Haferlach et al.,
2014; Papaemmanuil et al., 2013). In this
issue of Cancer Cell, Woll et al. (2014) uti-
lize this knowledge to integrate cellular
hierarchy with cancer genetics to show
definitively that lesions implicated as
driver mutations inMDS are present in he-
matopoietic stem cells (HSCs) as defined
by phenotypic cell surface markers.
The experimental design is elegant in its
simplicity. The authors reasoned that if the
genetic lesions occurred in stem cells,
theywould bepresent in the cells express-
ing stem cell markers; however, if the le-
sions transformed committed progenitor
cells that normally lack self-renewal po-
tential, then the lesions would be absentCancer Cellin the stem cell compartment. They first
demonstrated that cells in the phenotypi-
cally defined stem cell compartment
from MDS patients are functional stem
cells in xenograft assays. They then identi-
fied 34 somatic genetic lesions in 15 pa-
tient samples and demonstrated that all
of these mutations were present in the
stem cell compartment (Figure 1). There
were no cases of mutations found in the
bulk population of MDS cells that were
not also present in stem cells.
The authors next sought to delineate
how mutations were acquired during pro-
gression to AML in a subtype of MDS in
which the inciting lesion is a loss of the
long arm of chromosome 5 in stem cells25, June 16, 2014 ª2014 Elsevier Inc. 713
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gressed to AML, all of the newly acquired
mutations were detectable in the stem
cell compartment. In a second patient
with disease progression, oneof the newly
acquired mutations was detected in bulk
cells from the advanced lesion, but not in
the stem cell compartment, suggesting
that it was acquired in a downstream pro-
genitor that had acquired self-renewal po-
tential. Thus, paths to leukemic transfor-
mation can occur either in stem cells or
in progenitor cells.
These findings provide strong evidence
that mutations occurring in phenotypically
defined stem cells indeed drive the patho-
genesis of MDS. However, several ques-
tions remain unanswered. The authors
assume that mutations driving MDS
occurred in stem cells because they
found the mutations in cells defined by
having a particular set of surface markers.
Is it possible that acquisition of certain
mutations in committed progenitors ‘‘re-
programs’’ them to a stem cell phenotype,
expressing the canonical HSC surface
proteins? Which mutations must occur in
stem cells, and which can confer self-714 Cancer Cell 25, June 16, 2014 ª2014 Elsrenewal potential to committed progeni-
tors? Larger data sets, along with
functional experiments, will be needed to
answer these questions.
It has been suggested that therapies
eradicating the MDS stem cell are neces-
sary for curing disease. However, the
authors demonstrate that the stem and
progenitor compartment in low/interme-
diate risk MDS is minimally perturbed,
although the MDS clone has already
taken over the marrow at the time of dis-
ease presentation. Might therapies that
improve the functionality of the differenti-
ated progeny be effective? Nonetheless,
the work by Woll et al. (2014) does further
demonstrate that MDS is indeed a stem
cell disorder.REFERENCES
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GNAQ andGNA11 are frequently mutated in uveal melanoma, but they remain difficult therapeutic targets. In
this issue of Cancer Cell, Feng and colleagues and Yu and colleagues demonstrate that the oncogenic
activity of mutant GNAQ/11 ismediated at least in part through YAP, potentially uncovering a new therapeutic
strategy.Malignant melanomas that arise from the
iris, ciliary body, and choroid layers of
the eye—collectively referred to as uveal
melanomas—represent the most com-
mon primary cancer of the eye and the
second most common form of melanoma
(Harbour, 2012). Despite the availability
of highly effective treatments for eradi-cating the primary tumor, up to half of
affected individuals later develop meta-
static disease that is almost always fatal
within a few months. Until recently, the
identification of effective therapies for
metastatic uveal melanoma has been
hampered by a lack of known driver muta-
tions. This situation has changed in recentyears with the discovery of several com-
mon driver mutations, which has opened
the door to rational targeted therapies
(Harbour, 2012).
Mutually exclusive mutations in the G
protein-coupled receptor (GPCR) alpha
subunits GNAQ and GNA11 (encoding
Gq and G11 proteins, respectively) are
